{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:32:15Z","timestamp":1773772335582,"version":"3.50.1"},"reference-count":33,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":73,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The objective of this study was to compare the clinical efficacy and cost-effectiveness of IL-17 inhibitors (SEC, IXE, NTK) in the treatment of adult patients with ankylosing spondylitis (AS) in the healthcare system of the Russian Federation. Materials and methods. The study is a sub-analysis of a previously published systematic review and network meta-analysis of the comparative efficacy of biologics in adult patients with AS in the Russian Federation. NNT values were calculated for BASDAI 50 and ASAS 20\/40 after 16 weeks of therapy for all studied drugs. CpR was estimated for each biologic after 16 weeks and one year of therapy. Additionally, we carried out an assessment of the financial burden of the most cost-effective strategies for the treatment of AS. The use of NTK is characterized by an average of no more than three patients needed to treat to achieve one ASAS 20\/40 or BASDAI 50 response, while on IXE and SEC no more than 4\u20135 patients need to be treated, depending on the estimated effectiveness criterion. According to CpR estimate, NTK is the most cost-effective IL-17 inhibitor for the treatment of AS, both after 16 weeks and after one year of therapy. The obtained results make it possible to compare the effectiveness of IL-17 inhibitors from a clinical and economic points of view and can be used both in decision making on treatment strategies for individual patients and at the population level when deciding on the reimbursement of drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1134\/s1607672923700291","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:01:41Z","timestamp":1697216501000},"page":"173-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Pharmacoeconomic Effectiveness of Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis"],"prefix":"10.1134","volume":"511","author":[{"given":"T. V.","family":"Dubinina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. Z.","family":"Gaidukova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. A.","family":"Sableva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. V.","family":"Sapozhnikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. D.","family":"Sokolova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. G.","family":"Tolkacheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"7408_CR1","doi-asserted-by":"publisher","first-page":"112","DOI":"10.14412\/1996-7012-2018-3-112-119","volume":"12","author":"A.M. Lila","year":"2018","unstructured":"Lila, A.M., Dreval, R.O., and Shipitsyn, V.V., Assessment of organization of medical care and drug provision for patients with rheumatic diseases, and the socioeconomic burden of these diseases in the Russian Federation,\u00a0Sovrem. Revmatol. Zh., 2018, vol. 12, no. 3, pp. 112\u2013119.","journal-title":"Sovrem. Revmatol. Zh."},{"key":"7408_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.14412\/1996-7012-2022-1-20-25","volume":"16","author":"A.M. Lila","year":"2022","unstructured":"Lila, A.M., Dubinina, T.V., Dreval, R.O., Lapschina, S.A., and Zabotina, A.N. Medical and social significance and calculation of the economic burden of axial spondyloarthritis in the Russian Federation, Sovrem. Revmatol. Zh., 2022, vol. 16, no. 1, pp. 20\u201325.","journal-title":"Sovrem. Revmatol. Zh."},{"key":"7408_CR3","doi-asserted-by":"crossref","unstructured":"Garcia-Montoya, L., Gul, H., and Emery, P., Recent advances in ankylosing spondylitis: Understanding the disease and management, F1000Res., 2018, vol. 7, p.\u00a01000. Faculty Rev-1512.","DOI":"10.12688\/f1000research.14956.1"},{"key":"7408_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.14412\/1996-7012-2021-2-94-105","volume":"15","author":"Sh.F. Erdes","year":"2021","unstructured":"Erdes, Sh.F., Recent advances and prospects of axial spondyloarthritis\/ankylosing spondylitis treatment, Sovrem. Revmatol. Zh., 2021, vol. 15, no. 2, pp. 94\u2013105.","journal-title":"Sovrem. Revmatol. Zh."},{"key":"7408_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1089\/mab.2020.0022","volume":"39","author":"G.A. Katsevman","year":"2020","unstructured":"Katsevman, G.A., Mariscal, G., Barrios, C., Domenech- Fern\u00e1ndez, P., Ziembinski, C., and Bhatia, S., Efficacy and safety of anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a meta-analysis, Monoclon. Antibody Immunodiagn. Immunother., 2020, vol. 39, no. 5, pp. 160\u2013166.","journal-title":"Monoclon. Antibody Immunodiagn. Immunother."},{"key":"7408_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W. Park","year":"2016","unstructured":"Park, W., Yoo, D.H., Jaworski, J., Brzezicki, J., Gnylorybov, A., Kadinov, V., et al., Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study, Arthritis Res. Ther., 2016, vol.\u00a018, p.\u00a025.","journal-title":"Arthritis Res. Ther."},{"key":"7408_CR7","first-page":"646","volume":"58","author":"T.V. Dubinina","year":"2020","unstructured":"Dubinina, T.V., Gaydukova, I.Z., Sokolova, V.D., Mladov, V.V., and Tolkacheva, D.G., Effectiveness and safety of biologics for the treatment of ankylosing spondylitis: Systematic literature review and network meta-analysis of treatments approved in the Russian Federation, Nauchno-Prakt. \n               Revmatol., 2020, vol. 58, no. 6, pp. 646\u2013657.","journal-title":"Revmatol"},{"key":"7408_CR8","first-page":"2286","volume":"21","author":"H. Whitelock","year":"1994","unstructured":"Whitelock, H., Gaisford, P., and Calin, A., A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index, J. Rheumatol., 1994, vol. 21, no. 12, pp. 2286\u20132291.","journal-title":"J. Rheumatol"},{"key":"7408_CR9","first-page":"316","volume":"51","author":"M.A. Stone","year":"2004","unstructured":"Stone, M.A., Inman, R.D., Wright, JG, and Maetzel, A., Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics, Arthritis\u00a0Rheum., 2004, vol. 51, pp. 316\u2013320.","journal-title":"Arthritis\u00a0Rheum"},{"key":"7408_CR10","first-page":"133","volume":"23","author":"J. Zochling","year":"2005","unstructured":"Zochling, J. and Braun, J., Assessment of ankylosing spondylitis, Clin. Exp. Rheumatol., 2005, vol. 23, pp.\u00a0133\u2013141.","journal-title":"Clin. Exp. Rheumatol"},{"key":"7408_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.21037\/atm.2018.01.36","volume":"6","author":"Z. Zhang","year":"2018","unstructured":"Zhang, Z., Ambrogi, F., Bokov, A.F., Gu, H., de Beurs, E., and Eskaf, K., Estimate risk difference and number needed to treat in survival analysis, Ann. Transl. Med., 2018, vol. 6, no. 7, p. 120.","journal-title":"Ann. Transl. Med"},{"key":"7408_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijcp.12142","volume":"67","author":"L. Citrome","year":"2013","unstructured":"Citrome, L. and Ketter, T.A., When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed, Int. J. Clin. Pract., 2013, vol. 67, no.\u00a05, pp. 407\u2013411.","journal-title":"Int. J. Clin. Pract."},{"key":"7408_CR13","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D. Baeten","year":"2015","unstructured":"Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., et al., MEASURE 1 Study Group; MEASURE 2 Study Group. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis, N.\u00a0Engl. J. Med., 2015, vol. 373, no. 26, pp. 2534\u20132548.","journal-title":"N.\u00a0Engl. J. Med."},{"key":"7408_CR14","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1136\/ard.2004.035105","volume":"64","author":"J.C. Davis","year":"2005","unstructured":"Davis, J.C., van der Heijde, D.M., Braun, J., Dougados, M., Cush, J., Clegg, D., et al., Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks, Ann. Rheum. Dis., 2005, vol. 64, no. 11, pp. 1557\u20131562.","journal-title":"Ann. Rheum. Dis."},{"key":"7408_CR15","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"R.G. Lambert","year":"2007","unstructured":"Lambert, R.G., Salonen, D., Rahman, P., Inman, R.D., Wong, R.L., Einstein, S.G., et al., Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study, Arthritis Rheum., 2007, vol. 56, no. 12, pp.\u00a04005\u20134014.","journal-title":"Arthritis Rheum."},{"key":"7408_CR16","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","volume":"56","author":"D. Van der Heijde","year":"2017","unstructured":"Van der Heijde, D., Dougados, M., Landew\u00e9, R., Sieper, J., Maksymowych, W.P., Rudwaleit, M., et al., Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA, Rheumatology (Oxford), 2017, vol. 56, no. 9, pp. 1498\u20131509.","journal-title":"Rheumatology"},{"key":"7408_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J. Braun","year":"2003","unstructured":"Braun, J., Pham, T., Sieper, J., Davis, J., van der Linden, S., Dougados, M., et al., ASAS Working Group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis, Ann. Rheum. Dis., 2003, vol. 62, no. 9, pp. 817\u2013824.","journal-title":"Ann. Rheum. Dis."},{"key":"7408_CR18","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions, Higgins, J.P.T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., et al., Eds., version 6.3 (updated February 2022), Cochrane, 2022. www.training.cochrane.org\/handbook. Accessed June 1, 2022."},{"key":"7408_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1136\/bmj.317.7168.1309","volume":"317","author":"D.G. Altman","year":"1998","unstructured":"Altman, D.G., Confidence intervals for the number needed to treat, BMJ, 1998, vol. 317, no. 7168, pp.\u00a01309\u20131312.","journal-title":"BMJ"},{"key":"7408_CR20","unstructured":"State Register of Medicines. https:\/\/grls.rosminzdrav.ruPriceLims.aspx. Accessed June 1, 2022."},{"key":"7408_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"R.H. Dworkin","year":"2008","unstructured":"Dworkin, R.H., Turk, D.C., Wyrwich, K.W., Beaton, D., Cleeland, C.S., Farrar, J.T., et al., Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations, J. Pain, 2008, vol. 9, no. 2, pp. 105\u2013121.","journal-title":"J. Pain"},{"key":"7408_CR22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.7326\/0003-4819-126-9-199705010-00007","volume":"126","author":"H.J. McQuay","year":"1997","unstructured":"McQuay, H.J. and Moore, R.A., Using numerical results from systematic reviews in clinical practice, Ann. Intern. Med., 1997, vol. 126, pp. 712\u2013720. https:\/\/doi.org\/10.7326\/0003-4819-126-9-199705010-00007","journal-title":"Ann. Intern. Med."},{"key":"7408_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","volume":"117","author":"L. Citrome","year":"2008","unstructured":"Citrome, L., Compelling or irrelevant? Using number needed to treat can help decide, Acta Psychiatr. Scand., 2008, vol. 117, pp. 412\u2013419.","journal-title":"Acta Psychiatr. Scand"},{"key":"7408_CR24","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/1756-185X.13635","volume":"22","author":"D. Kim","year":"2019","unstructured":"Kim, D., Kim, H., Cho, S., and Park, M.C., A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective, Int. J. Rheum. Dis., 2019, vol. 22, no. 9, pp. 1630\u20131637.","journal-title":"Int. J. Rheum. Dis."},{"key":"7408_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/bmj.38954.689583.DE","volume":"333","author":"C.M. McVeigh","year":"2006","unstructured":"McVeigh, C.M. and Cairns, A.P., Diagnosis and management of ankylosing spondylitis, BMJ, 2006, vol.\u00a0333, pp. 581\u2013585.","journal-title":"BMJ"},{"key":"7408_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.55563\/clinexprheumatol\/dz0xrd","volume":"39","author":"S. D\u2019Angelo","year":"2021","unstructured":"D\u2019Angelo, S., Malavolta, N., Scambi, C., Salvarani, C., Caso, F., Tirri, E., et al., Quality of life and therapeutic management of axial spondyloarthritis patients in Italy: a 12-month prospective observational study, Clin. Exp. Rheumatol., 2021, vol. 39, no. 5, pp.\u00a0961\u2013969.","journal-title":"Clin. Exp. Rheumatol."},{"key":"7408_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.17749\/2070-4909\/farmakoekonomika.2022.128","volume":"15","author":"V.D. Sokolova","year":"2022","unstructured":"Sokolova, V.D., Sableva, N.A., Mladov, V.V., and Tolkacheva, D.G., The effectiveness of targeted medications in the treatment of adult patients with moderate and severe vulgar psoriasis in the Russian Federation: updating a systematic review, Farmakoekonomika, 2022, vol. 15, no. 1, pp. 131\u2013144.","journal-title":"Farmakoekonomika"},{"key":"7408_CR28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.17116\/medtech20214302151","volume":"43","author":"D.G. Tolkacheva","year":"2021","unstructured":"Tolkacheva, D.G., Mladov, V.V., and Sokolova, V.D., The effectiveness of genetically engineered biological and targeted synthetic drugs registered in Russia for the treatment of adult patients with active psoriatic arthritis: a systematic review and network meta-analysis, Med. Technol. Assess. Choice, 2021, vol. 43, no. 2, pp. 51\u201366.","journal-title":"Med. Technol. Assess. Choice"},{"key":"7408_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.17749\/2070-4909\/farmakoekonomika.2021.095","volume":"14","author":"A.V. Rudakova","year":"2021","unstructured":"Rudakova, A.V., Tolkacheva, D.G., and Sokolova, V.D., Pharmacoeconomical aspects of the therapy of moderate and severe psoriatic arthritis, Farmakoekonomika, 2021, vol. 14, no. 2, pp. 116\u2013123.","journal-title":"Farmakoekonomika"},{"key":"7408_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.14412\/1996-7012-2020-4-39-49","volume":"14","author":"V.I. Mazurov","year":"2020","unstructured":"Mazurov, V.I., Erdes, S.F., Gaydukova, I.Z., Dubinina, T.V., Pristrom, A.M., Kunder, E.V., et al. Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: Results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA, Sovrem. Revmatol. Zh., 2020, vol. 14, no. 4, pp. 39\u201349.","journal-title":"Sovrem. Revmatol. Zh."},{"key":"7408_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.14412\/1996-7012-2021-1-128-135","volume":"15","author":"R.O. Dreval","year":"2021","unstructured":"Dreval, R.O., Cost-effectiveness study of treatment with biologic disease-modifying antirheumatic drugs in adult patients with active ankylosing spondylitis, Sovrem. Revmatol. Zh., 2021, vol. 15, no. 1, pp. 128\u2013135.","journal-title":"Sovrem. Revmatol. Zh."},{"key":"7408_CR32","unstructured":"Khudonogov, I.Yu., Tegza, V.Yu., Bakanev, O.Yu., Korin, V.V., Sapozhnikov, K.V., and Koloyarov, S.N., On motivational criteria for the quality of medical care. Economics, management and marketing in military and civil health care, in Proc. Conf. \u201cEconomics, Management, and Marketing in Military and Civil Health Care,\u201d 2014, pp. 39\u201344."},{"key":"7408_CR33","unstructured":"Paulov, A.A., Parfenov, S.A., and Petrova, P.V., The role of comorbidity assessment in the course of medical and social expertise. Fundamental science and clinical medicine\u2014man and his health, in Proc. XXV International Medical and Biological Conference of Young Researchers, 2022, pp. 397\u2013398."}],"updated-by":[{"DOI":"10.1134\/s1607672923050058","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000}}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672923700291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672923700291","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672923700291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:16:47Z","timestamp":1773760607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672923700291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7408"],"URL":"https:\/\/doi.org\/10.1134\/s1607672923700291","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Erratum to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1134\/S1607672923050058","URL":"https:\/\/doi.org\/10.1134\/S1607672923050058","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}